tiprankstipranks
Advertisement
Advertisement

KALV Stock Latest News

Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
RatingsEkterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
2d ago
KALV
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
PremiumThe Fly
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
10d ago
KALV
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
PremiumRatings
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
14d ago
KALV
KalVista price target lowered to $28 from $29 at Citizens
PremiumThe Fly
KalVista price target lowered to $28 from $29 at Citizens
14d ago
KALV
KalVista price target raised to $42 from $39 at Stifel
PremiumThe Fly
KalVista price target raised to $42 from $39 at Stifel
14d ago
KALV
KalVista reports 8M EPS ($2.03) vs. ($2.30) last year
PremiumThe FlyKalVista reports 8M EPS ($2.03) vs. ($2.30) last year
15d ago
KALV
KalVista sees cash runway through profitability
Premium
The Fly
KalVista sees cash runway through profitability
15d ago
KALV
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
Premium
Ratings
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
28d ago
KALV
KalVista announces new data from sebetralstat clinical trial program
PremiumThe Fly
KalVista announces new data from sebetralstat clinical trial program
1M ago
KALV
KalVista announces inclusion of Ekterly on Hereditary Angioedema guideline
PremiumThe Fly
KalVista announces inclusion of Ekterly on Hereditary Angioedema guideline
2M ago
KALV
KalVista price target raised to $35 from $30 at TD Cowen
PremiumThe Fly
KalVista price target raised to $35 from $30 at TD Cowen
2M ago
KALV
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
PremiumCompany Announcements
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
3M ago
KALV
KalVista price target raised to $37 from $27 at H.C. Wainwright
PremiumThe FlyKalVista price target raised to $37 from $27 at H.C. Wainwright
3M ago
KALV
KalVista price target raised to $29 from $28 at Citizens
Premium
The Fly
KalVista price target raised to $29 from $28 at Citizens
3M ago
KALV
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
Premium
Ratings
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
3M ago
KALV
KalVista Highlights Strong EKTERLY Launch and Global Uptake
PremiumCompany Announcements
KalVista Highlights Strong EKTERLY Launch and Global Uptake
3M ago
8K
KALV
KalVista price target raised to $32 from $28 at Needham
PremiumThe Fly
KalVista price target raised to $32 from $28 at Needham
3M ago
KALV
LQDA
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
PremiumRatings
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
3M ago
KALV
KalVista says MHLW in Japan grants marketing, manufacturing approval for Ekterly
PremiumThe Fly
KalVista says MHLW in Japan grants marketing, manufacturing approval for Ekterly
4M ago
KALV
Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
PremiumRatingsPromising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
4M ago
KALV
Pharvaris price target raised to $50 from $44 at Oppenheimer
Premium
The Fly
Pharvaris price target raised to $50 from $44 at Oppenheimer
4M ago
KALV
PHVS
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
Premium
Ratings
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
4M ago
KALV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >